Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
JAK Inhibitors
•
Gastroenterology
•
General Hepatology
•
Cirrhosis
•
Hepatology
•
Metabolic Dysfunction-Associated Liver Diseases
Do you avoid JAK inhibitors in patients with a history of liver disease including NAFLD or cirrhosis?
Related Questions
Have you utilized JAK inhibitors in patients on dialysis?
Are you comfortable trying a different JAK inhibitor in patients with prior JAK inhibitor allergy?
What is your approach to methotrexate use (or avoidance) in patients with varying MTHFR mutations?
For patients who do not have access to biologic therapies, what are some csDMARD combination pearls or tips that you have that have particular efficacy in different rheumatologic diseases?
How do you approach treatment of a patient with active RA and a history of Lynch Syndrome?
How do you manage transaminitis in a patient receiving TNF alpha inhibitors?
What is your approach to differentiating RA-ILD from medication toxicity (I.e. from methotrexate)?
What is your approach to assessing inflammatory arthritis flares in joints that have been replaced (such as knees)?
Is there a role for nitazoxanide for treatment of norovirus gastroenteritis in immunocompromised patients?
Do you obtain liver biopsy to confirm the diagnosis of cirrhosis if cirrhotic liver morphology is noted on imaging?